Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
26242
Description
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Screening/Enrollment
Mots-clés
Versions (6)
- 25/08/2017 25/08/2017 -
- 25/08/2017 25/08/2017 -
- 25/08/2017 25/08/2017 -
- 13/10/2017 13/10/2017 -
- 23/10/2017 23/10/2017 -
- 12/12/2017 12/12/2017 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
13 octobre 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Screening/Enrollment GSK study Chronic Coronary Heart Disease NCT00799903
Screening/Enrollment GSK study Chronic CHD NCT00799903
- StudyEvent: ODM
Similar models
Screening/Enrollment GSK study Chronic CHD NCT00799903
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Subject initials
Item
1. Subject initials
text
Date of birth
Item
2. Date of birth
date
eGFR
Item
3. eGFR value used for screening
integer
screen failure
Item
4. Was this subject a screen failure?
boolean
Inclusion exclusion criteria
Item
[F01] Did not meet inclusion/exclusion criteria
boolean
Withdrawal of consent
Item
[F10] Subject withdrew consent prior to randomisation
boolean
Study closed/terminated
Item
[F06] Study closed/terminated prior to randomisation
boolean
Lost to follow up
Item
[F07] Lost to follow up prior to randomisation
boolean
Item Group
If subject did not meet inclusion/exclusion criteria, specify:
Inclusion Criteria sex pregnancy
Item
[I02] Inclusion Criteria 2: Male or female at least 18 years old at screening and females postmenopausal or using highly effective method to avoid pregnancy
boolean
Inclusion Criteria statin therapy
Item
[I03] Inclusion Criteria 3: Current treatment with statin therapy unless contraindicated
boolean
Inclusion Criteria Chronic CHD
Item
[I04] Inclusion Criteria 4: Chronic CHD documented
boolean
Inclusion Criteria additional predictors of CV risk
Item
[I05] Inclusion Criteria 5: At least one additional predictor of CV risk
boolean
Exclusion Criteria Planned coronary PCI or CABG
Item
[E01] Exclusion Criteria 1: Planned coronary revascularization (PCI or CABG) or any other major surgical procedure
boolean
Exclusion Criteria abnormal liver function
Item
[E02] Exclusion Criteria 2: Current liver disease, known hepatic or biliary abnormalities evidence of abnormal liver function tests
boolean
Exclusion Criteria renal impairment
Item
[E03] Exclusion Criteria 3: Severe renal impairment or history of nephrectomy or kidney transplant
boolean
Exclusion Criteria heart failure
Item
[E04] Exclusion Criteria 4: Current severe heart failure
boolean
Exclusion Criteria hypertension
Item
[E05] Exclusion Criteria 5: Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy
boolean
Exclusion Criteria life expectancy less than 2 years
Item
[E06] Exclusion Criteria 6: Any life-threatening condition with life expectancy less than 2 years
boolean
Exclusion Criteria asthma
Item
[E07] Exclusion Criteria 7: Severe asthma that is poorly controlled on pharmacotherapy
boolean
Exclusion Criteria pregnancy
Item
[E08] Exclusion Criteria 8: Positive pregnancy test or is known to be pregnant or lactating
boolean
Exclusion Criteria allergy
Item
[E09] Exclusion Criteria 9: History of anaphylaxis, anaphylactoid reactions severe allergic responses
boolean
Exclusion Criteria Alcohol or drug abuse
Item
[E10] Exclusion Criteria 10: Alcohol or drug abuse within the past 6 months, or current mental condition which may affect study compliance
boolean
Exclusion Criteria CYP3A4 inhibitors
Item
[E11] Exclusion Criteria 11: Current or planned chronic administration of strong oral or injectable CYP3A4 inhibitors
boolean
Exclusion Criteria Lp-PLA2 activity
Item
[E12] Exclusion Criteria 12: Subjects with both parents of Japanese, Chinese, or Korean ancestry with Lp-PLA2 activity less or eq 20 nmol/min/mL
boolean
Exclusion Criteria exposure to darapladib
Item
[E13] Exclusion Criteria 13: Previous exposure to darapladib (SB-480848)
boolean
Exclusion Criteria Use of other IP
Item
[E14] Exclusion Criteria 14: Use of another investigational product within 30 days or 5 half-lives preceding the first dose of darapladib or matching placebo
boolean
Exclusion Criteria study of investigational device
Item
[E15] Exclusion Criteria 15: Currently in a study of an investigational device
boolean
Exclusion Criteria other
Item
[E16] Exclusion Criteria 16: Any other reason the investigator deems the subject to be unsuitable for the study
boolean
Exclusion Criteria other specification
Item
[E16] Exclusion Criteria 16, specify:
text